Intramuscular Olanzapine Depot

DRUG4 trials

Sponsors

Eli Lilly and Company

Conditions

Schizoaffective DisorderSchizophreniaSchizophrenic Disorders

Phase 1

Pharmacokinetic Characterization of Intramuscular Olanzapine Depot

CompletedNCT00094640

Eli Lilly and CompanySchizoaffective Disorder, Schizophrenia

Updated: 2006-07-19

Phase 3

Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder

CompletedNCT00088465

Eli Lilly and CompanySchizoaffective Disorder, Schizophrenic Disorders

Start: 2004-08-31End: 2010-12-31Updated: 2012-01-11

Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia

CompletedNCT00088478

Eli Lilly and CompanySchizophrenia

Start: 2004-06-30End: 2005-04-30Updated: 2007-06-12

Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia

CompletedNCT00088491

Eli Lilly and CompanySchizophrenic Disorders

Start: 2004-06-30End: 2006-10-31Updated: 2007-06-22

Related Papers

A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection.

2014-01-1411 citations

Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study.

2013-09-169 citations

Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysis.

2012-08-313 citations

Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data.

2012-05-309 citations

Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia.

2012-01-3110 citations

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia.

2011-09-2315 citations

Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia.

2011-02-1512 citations

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases.

2010-06-1075 citations

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism.

2010-06-1060 citations